Welcome, Guest. Please login or register.
June 03, 2023, 01:43:26 pm

Login with username, password and session length

  • Total Posts: 55098
  • Total Topics: 4847
  • Online Today: 40
  • Online Ever: 1314
  • (June 22, 2016, 05:23:42 am)
Users Online
Users: 0
Guests: 36
Total: 36


Welcome to the Hep Forums, a round-the-clock discussion area for people who have Fatty Liver Disease, Hepatitis B, C or a co-infection, their friends and family and others with questions about hepatitis and liver health. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Hep Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: Mavyret Is Highly Effective Against Hep C in Those With a Drug-Use History  (Read 3097 times)

0 Members and 1 Guest are viewing this topic.

Offline Hep Editors

  • Member
  • Posts: 784
    • Hep Mag
People who currently use drugs or have a history of doing so, including those taking medication-assisted treatment (MAT) to treat opioid use disorder, have a high hepatitis C virus (HCV) cure rate following direct-acting antiviral treatment with Mavyret (glecaprevir/pibrentasvir).

Mavyret is approved to treat all genotypes of HCV and can be used in combination with MAT. The regimen can be completed in as little as eight weeks, including among those with compensated cirrhosis (the milder form of the severe liver disease).

Alessio Aghemo, MD, of Humanitas University and Research Hospital in Rozzano, Italy, presented results from a pooled analysis of clinical trials and real-world studies of Mavyret at The Liver Meeting, the Annual Meeting of the American Association for the Study of Liver Diseases, in Boston this month.



© 2023 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.